User:Mr. Ibrahem/Teduglutide

Mr. Ibrahem/Teduglutide
Clinical data
Trade names	Gattex, Revestive, others
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN;
Routes of; administration	Subcutaneous injection
Drug class	Glucagon-like peptide-2 (GLP-2)
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	88%
Metabolism	Proteolysis
Elimination half-life	2 h
Identifiers
	IUPAC name L-histidylglycyl-L-α-aspartylglycyl-L-seryl-L-phenylalanyl-L-seryl-L-α-aspartyl-L-α-glutamyl-L-methionyl-L-asparaginyl-L-threonyl-L-isoleucyl-L-leucyl-L-α-aspartyl-L-asparaginyl-L-leucyl-L-alanyl-L-alanyl-L-arginyl-L-α-aspartyl-L-phenylalanyl-L-isoleucyl-L-asparaginyl-L-tryptophyl-L-leucyl-L-isoleucyl-L-glutaminyl-L-threonyl-L-lysyl-L-isoleucyl-L-threonyl-L-aspartic acid;
Chemical and physical data
Formula	C164H252N44O55S
Molar mass	3752.13 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O;
	InChI InChI=1S/C164H252N44O55S/c1-21-77(11)126(156(255)187-95(44-46-114(167)214)141(240)206-130(83(17)211)160(259)186-93(42-33-34-49-165)140(239)202-129(80(14)24-4)159(258)208-131(84(18)212)161(260)200-111(163(262)263)66-125(230)231)203-151(250)100(54-76(9)10)189-145(244)103(57-88-67-175-92-41-32-31-40-90(88)92)192-147(246)105(60-116(169)216)199-157(256)127(78(12)22-2)204-152(251)102(56-87-38-29-26-30-39-87)190-149(248)109(64-123(226)227)195-137(236)94(43-35-50-174-164(171)172)183-134(233)82(16)179-133(232)81(15)180-142(241)98(52-74(5)6)188-146(245)104(59-115(168)215)194-150(249)110(65-124(228)229)196-143(242)99(53-75(7)8)198-158(257)128(79(13)23-3)205-162(261)132(85(19)213)207-153(252)106(61-117(170)217)193-139(238)97(48-51-264-20)185-138(237)96(45-47-120(220)221)184-148(247)108(63-122(224)225)197-155(254)113(72-210)201-144(243)101(55-86-36-27-25-28-37-86)191-154(253)112(71-209)182-119(219)70-177-136(235)107(62-121(222)223)181-118(218)69-176-135(234)91(166)58-89-68-173-73-178-89/h25-32,36-41,67-68,73-85,91,93-113,126-132,175,209-213H,21-24,33-35,42-66,69-72,165-166H2,1-20H3,(H2,167,214)(H2,168,215)(H2,169,216)(H2,170,217)(H,173,178)(H,176,234)(H,177,235)(H,179,232)(H,180,241)(H,181,218)(H,182,219)(H,183,233)(H,184,247)(H,185,237)(H,186,259)(H,187,255)(H,188,245)(H,189,244)(H,190,248)(H,191,253)(H,192,246)(H,193,238)(H,194,249)(H,195,236)(H,196,242)(H,197,254)(H,198,257)(H,199,256)(H,200,260)(H,201,243)(H,202,239)(H,203,250)(H,204,251)(H,205,261)(H,206,240)(H,207,252)(H,208,258)(H,220,221)(H,222,223)(H,224,225)(H,226,227)(H,228,229)(H,230,231)(H,262,263)(H4,171,172,174)/t77-,78-,79-,80-,81-,82-,83+,84+,85+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,126-,127-,128-,129-,130-,131-,132-/m0/s1 ; Key:CILIXQOJUNDIDU-ASQIGDHWSA-N ;
	(verify)

Teduglutide, sold under the brand names Gattex among others is a medication used for short bowel syndrome.^[1] Specifically it is used for people who require parenteral nutrition.^[1] It is given by injection just under the skin.^[1]

Common side effects include abdominal pain, nausea, fluid overload, allergic reactions, and headache.^[1] Other potential side effects may include tumors, intestinal obstruction, gall bladder disease, and pancreatitis.^[1] Use during pregnancy appears to be safe.^[2] It is similar to the bodies own glucagon-like peptide-2 (GLP-2), which increases the uptake of nutrients from the intestines.^[3]

Teduglutide was approved for medical use in the United States and Europe in 2012.^[1]^[3] At a dose of 5 mg per day, in the United Kingdom it costs the NHS about £15,000 a month as of 2021.^[4] This amount in the United States costs about 36,000 per month.^[5]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Teduglutide Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 24 September 2021.
^ "Teduglutide (Gattex) Use During Pregnancy". Drugs.com. Archived from the original on 25 January 2021. Retrieved 24 September 2021.
^ ^a ^b "Revestive". Archived from the original on 12 November 2020. Retrieved 24 September 2021.
^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 54. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
^ "Specialty drug prices soaring past six figures per year". KSAT. 26 July 2019. Archived from the original on 26 November 2020. Retrieved 24 September 2021.

[AHFS2021-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Teduglutide Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 24 September 2021.

[2] "Teduglutide (Gattex) Use During Pregnancy". Drugs.com. Archived from the original on 25 January 2021. Retrieved 24 September 2021.

[EPAR2021-3] "Revestive". Archived from the original on 12 November 2020. Retrieved 24 September 2021.

[BNF80-4] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 54. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[5] "Specialty drug prices soaring past six figures per year". KSAT. 26 July 2019. Archived from the original on 26 November 2020. Retrieved 24 September 2021.

[1]

[2]

[3]

[4]

[5]